Bortezomib is a 26S proteasome inhibitor initially used in MM treatment based upon expectation that bortezomib could inhibit NF-κB activity by preventing proteasomal degradation of IκBα. This evidence concerns the gene NFKB1 and Miyoshi myopathy.